Plain-English translation of NCT06220201 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which is a type of immunotherapy made from your own immune cells. Researchers are studying whether this medication is safe and whether it helps people with multiple sclerosis (both relapsing and progressive forms) or severe myasthenia gravis that hasn't responded well to other treatments. The goal is to understand how well this treatment works and what side effects it may cause.
Multiple sclerosis and myasthenia gravis are autoimmune diseases where the immune system attacks nerve cells and muscles. Some patients don't respond well enough to standard medications, and researchers believe that this new type of cell therapy might help by resetting the immune system in a different way than current treatments.
If you qualify, you would receive the medication through an infusion at the study center. The trial will track your safety and how you respond over time with regular visits to the clinic for blood tests, physical exams, and symptom checks. This is a Phase 1 study, meaning researchers are primarily focused on understanding safety and finding the right dose, so you would be carefully monitored throughout your participation.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States